Effectiveness of Bivalent MRNA Booster Vaccination Against SARS-CoV-2 Omicron Infection, the Netherlands, September to December 2022

Overview

Journal Euro Surveill

Specialty Infectious Diseases

Date 2023 Feb 16

PMID 36795500

Authors

Anne J Huiberts

Brechje de Gier

Christina E Hoeve

Hester E de Melker

Susan Jm Hahne

Gerco Den Hartog

Janneke Hhm van de Wijgert

Susan van den Hof

Mirjam J Knol

Affiliations

Soon will be listed here.

Abstract

We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.

Citing Articles

Using SARS-CoV-2 nucleoprotein antibodies to detect (re)infection.

Hoeve C, Hoeve C, Neppelenbroek N, Neppelenbroek N, Vos E, Vos E Epidemiol Infect. 2025; 153:e38.

PMID: 39915267 PMC: 11869087. DOI: 10.1017/S095026882500010X.

Impact of Repeated Variant Exposures on Cellular and Humoral Immunogenicity Induced by SARS-CoV-2 Vaccines.

Fernandez-Ciriza L, Del Pozo J, Betanzos N, Gonzalez A, Fernandez-Montero A, Carmona-Torre F Vaccines (Basel). 2025; 12(12.

PMID: 39772069 PMC: 11680034. DOI: 10.3390/vaccines12121408.

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection-Increasing Community Access to Testing Program, United States, January-September 2023.

Ciesla A, Mak J, Roper L, Fleming-Dutra K, Smith Z, Wiegand R Influenza Other Respir Viruses. 2024; 18(11):e70038.

PMID: 39522959 PMC: 11550894. DOI: 10.1111/irv.70038.

Methodology of comparative studies on the relative effectiveness of COVID-19 vaccines: a systematic review.

Bolormaa E, Shim J, Choi Y, Kwon D, Choe Y, Choe S Osong Public Health Res Perspect. 2024; 15(5):395-408.

PMID: 39511961 PMC: 11563719. DOI: 10.24171/j.phrp.2024.0063.

Cohort profile: an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - the VAccine Study COVID-19 (VASCO).

Huiberts A, Hoeve C, Kooijman M, de Melker H, Hahne S, Grobbee D BMJ Open. 2024; 14(10):e085388.

PMID: 39401962 PMC: 11474871. DOI: 10.1136/bmjopen-2024-085388.

References

Link-Gelles R, Ciesla A, Fleming-Dutra K, Smith Z, Britton A, Wiegand R . Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(48):1526-1530. PMC: 9721148. DOI: 10.15585/mmwr.mm7148e1. View

Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C . Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023; 23(5):556-567. PMC: 10014083. DOI: 10.1016/S1473-3099(22)00801-5. View

Huiberts A, de Gier B, Hoeve C, de Melker H, Hahne S, Den Hartog G . Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study. Int J Infect Dis. 2023; 133:36-42. PMC: 10118053. DOI: 10.1016/j.ijid.2023.04.401. View

Andersson N, Thiesson E, Baum U, Pihlstrom N, Starrfelt J, Faksova K . Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study. BMJ. 2023; 382:e075286. PMC: 10364194. DOI: 10.1136/bmj-2022-075286. View